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Abstract
The search for diagnostic and prognostic biomarkers for neurodegenerative conditions is of high importance, since these
disorders may present difficulties in differential diagnosis. Biomarkers with high sensitivity and specificity are required.
Neurofilament light chain (NfL) is a unique biomarker related to axonal damage and neural cell death, which is elevated in a
number of neurological disorders, and can be detected in cerebrospinal fluid (CSF), as well as blood, serum, or plasma samples.
Although the NfL concentration in CSF is higher than that in blood, blood measurement may be easier in practice due to its lesser
invasiveness, reproducibility, and convenience.Many studies have investigated NfL in both CSF and serum/plasma as a potential
biomarker of neurodegenerative disorders. Neuroimaging biomarkers can also potentially improve detection of CNS-related
disorders at an early stage. Magnetic resonance imaging (MRI) and diffusion tensor imaging (DTI) are sensitive techniques to
visualize neuroaxonal loss. Therefore, investigating the combination of NfL levels with indices extracted from MRI and DTI
scans could potentially improve diagnosis of CNS-related disorders. This review summarizes the evidence for NfL being a
reliable biomarker in the early detection and disease management in several CNS-related disorders. Moreover, we highlight the
correlation between MRI and NfL and ask whether they can be combined.
Keywords Neurofilament light chain .Biomarker .Neurodegenerative disorders .Magnetic resonance imaging .Diffusion tensor
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Introduction
The past decade has seen impressive efforts in the search
for biomarkers for neurodegenerative diseases. Based on
the National Institutes of Health (NIH) definition, a “bio-
marker” is a characteristic that can be objectively mea-
sured and evaluated as an indicator of normal biological
processes, pathogenic processes, or pharmacologic re-
sponses to a therapeutic intervention [1]. Depending on
their applications, biomarkers can be categorized either
as imaging biomarkers or molecular biomarkers. They
can also be classified based on their chief application
including, diagnostic, staging, prognosis, or monitoring
treatment response [2].
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Recently, it has been recognized that some common mo-
lecular mechanisms including protein aggregation and inclu-
sion body formation are shared between almost all CNS-
related disorders that had been previously considered unrelat-
ed and biologically distinct [3]. Each type of neurodegenera-
tive disease is identified by one specific protein that accumu-
lates, often in an aggregated form. Since post-mortem pathol-
ogy has been classically used for unambiguous diagnosis of
such diseases, obtaining a biopsy from the brain of a living
individual is fraught with difficulty. Therefore, biochemical
and molecular imaging biomarkers have suggested that will
allow pathological changes to be detected in the brain even
without biopsy [4, 5]. These developments have helped clini-
cians to apply accessible, simple, and practical methods for
early diagnosis, differential diagnosis, follow-up, and treat-
ment assessment of CNS-related disorders [6]. Biochemical
biomarkers can be obtained from tissue, cerebrospinal fluid
(CSF), or blood samples. However, because of difficulty in
obtaining tissue-based biopsies for diagnostic goals or for lon-
gitudinal studies, the use of biological fluids, including blood
and CSF biomarkers, has received the majority of attention in
CNS-related disorders [7]. This review is focused on the use
of neurofilament light chain (NfL), a neuron-specific protein
component released after axonal damage, as a potential bio-
marker of CNS-related disorders. Elevated NfL concentra-
tions in CSF and serum/plasma have been shown to serve as
a potential biomarker for axonal injury in several neurological
disorders [8]. Many studies have investigated the potential
role of this protein in diagnosis, prognosis, and monitoring
of CNS-related disorders. In addition to this fluid-based bio-
marker, MRI indices have also been considered as imaging
biomarkers, and the correlation between these two types of
biomarkers has been considered.
Neurofilament Light Chain as a Biomarker
for CNS-Related Disorders
Neurofilaments (NFs) are the most important cytoskeletal pro-
teins in myelinated subcortical axons [9–12]. NFs principally
consist of four subunits: NF light (NfL), NF medium (NfM),
and NF heavy (NfH) chains together with alpha-internexin
[10].
In contrast to other ubiquitous cytoskeletal proteins such as
actin, NFs are specific and abundant in the neuro-axonal com-
partments [10]. The NfL polypeptide is the most abundant
intermediate filament in neurons and axons and plays a sub-
stantial role in the assembly and maintenance of the axonal
cytoskeleton.
Disruption of the axonal membrane releases NFs into the
interstitial fluid, and ultimately into both CSF and blood. NfL
has the lowest molecular weight and the highest solubility
compared to other subunits; therefore, it diffuses more easily
from the parenchyma into the CSF after axonal degeneration
or neuronal death or disruption [13].
An abnormal increase of NF proteins in the CSF (including
NfL and phosphorylated Nf heavy chain, pNfH) has been
shown to be associated with neuronal death and axonal degen-
eration in a variety of disorders, including Alzheimer’s disease
(AD), Parkinson’s disease (PD), multiple sclerosis (MS), and
amyotrophic lateral sclerosis (ALS) (Table 1) [25].
Autoantibodies against neuronal and axonal antigens not
only are related to neurodegenerative disorders, but also are
found in other CNS diseases [26]. In these diseases, tissue
disruption occurs through various mechanisms, including ac-
tivation of oligodendrocytes, complement activation, or phys-
iological impairments [27]. It is has been shown that when
these antibodies against proteins of the cytoskeleton interact
with neurons, cytoskeleton functions are impaired leading to
neurodegeneration [28]. The deleterious effects of these anti-
NF antibodies have been established in several experimental
investigations. Immunization with NfL increased anti-NfL an-
tibodies in mice [28]. In the immunized animals, axonal inju-
ries and neurological symptoms were triggered. Anti-
neurofilament antibodies seem to show damaging effects, par-
ticularly in the intraneuronal compartments, but the possible
existence of favorable effects should not be neglected. Prior
studies of anti-NfH antibodies in the CSF and serum showed
their presence, not only in subjects with different neurological
disorders, but also to some extent in normal individuals [29,
30]. It has been suggested that their presence might play a role
in maintaining cognitive function. Talja et al. also showed that
in Down’s syndrome patients with mild to moderate disability,
there was greater prevalence of serum antibodies against the
NfH protein in comparison with patients with more severe
disabilities [31].
Since obtaining CSF is considered too invasive, and CSF is
not suitable for repetitive sampling or long-term follow-up,
sequential blood samples would be a preferable alternative
for measuring a biomarker. Therefore, blood Nf levels could
be useful as a noninvasive, reproducible, and rapid biomarker
for both predicting and monitoring disease progression, and
for assessing the efficiency or toxicity of future neuroprotec-
tive treatment approaches (Fig. 1) [32].
NfL Levels in Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS, also known as motor
neuron disease) is an inexorable progressive disorder affecting
the spinal cord and cerebellum resulting in motor neurodegen-
eration and ataxia (Fig. 2) [25]. ALS may be challenging to
diagnose, particularly in the early stages of the disease, be-
cause of its resemblance to other neurodegenerative diseases.
Since the mean time to diagnosis is 16–19 months from the
appearance of the first symptom, misdiagnosis is common.
Although there is no effective therapy, early treatment with
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riluzole seems to decelerate the disease progression and ex-
tend survival. Therefore, establishing a sensitive biomarker
for diagnosis, prognostic stratification, and assessment of dis-
ease severity is required [32].
Many studies have shown that the levels of NfL in CSF
provide both diagnostic and prognostic information for ALS
[10, 33–36]. These studies all showed that NfL levels in CSF
and blood-based sample were higher in ALS patients com-
pared to control groups without any signs of CNS structural
disruption [10, 33–36]. Moreover, the sensitivity and specific-
ity have been evaluated in many of these studies using receiv-
er operating curve (ROC) analysis, suggesting that NfL con-
centration may reflect the neurodegenerative process in ALS
[25]. The increased amounts of CSF-NfL found in ALS could
be due to the higher concentration of axonal proteins in motor
neurons compared to other neuronal populations. In addition,
the large myelinated axons in the motor neurons which are
damaged could result in the release of more Nfs in the CSF
[33]. High CSF-NfL concentrations in ALS are a predictor of
a short TTG (time to generalization). These results confirm the
role of NfL as a prognostic biomarker in ALS [37].
Using ROC analysis, Tortelli et al. showed that an optimal
NfL cutoff value of 1981 ng/L discriminated between ALS
patients and controls. The correlation between CSF-NfL
levels and the incidence of ALS was confirmed by multivar-
iate logistic regression. CSF-NfL negatively correlated with
the diagnostic delay and positively correlated with the pro-
gression rate. The significant relationship between CSF-NfL
levels and disease progression suggests that NfL may be a
suitable biomarker for disease activity and progression in
ALS [33].
Considering that ALS is known to be a heterogeneous dis-
ease, and that Nfs are markers of the general process of neu-
rodegeneration and axonal damage [33], researchers have
attempted to evaluate NfL levels in similar diseases such as
AD and Guillain-Barré syndrome (GBS) [10]. CSF-NfL con-
centrations in ALS were generally higher than in AD and
GBS. Moreover, CSF and serum NfL levels correlated with
age in GBS and ALS. After correction for age, a significant
difference remained between GBS and ALS, but not for AD
versus controls. A similar study by Gianni et al. [36] on
frontotemporal dementia (FTD) and ALS patients found that
an NfL cutoff of 1843.52 pg/mL provided optimal discrimi-
nation between patients with ALS and other patients at a sen-
sitivity of 81.9% and a specificity of 80.5%. A lower cutoff of
1380.48 pg/mL was most appropriate for differentiation be-
tween patients with ALS and controls at a sensitivity of 88.7%
and a specificity of 89.4%. Conversely, a higher cutoff of
3113.03 pg/mL was optimal for differentiating between ALS
and FTD, or motor neuropathies (MNs) with a sensitivity of
70.2% and a specificity of 86.8%. [36].
Studies in which both CSF and blood-based samples were
evaluated as biomarkers in ALS have confirmed the goodTa
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correlation between CSF and serum/plasma levels [10, 34,
35]. For example, Lu et al. [35] showed that CSF, serum,
and plasma NfL levels were higher in ALS patients, and could
differentiate them from healthy controls with high sensitivity
and specificity (cutoff 1781 pg/mL, 36 pg/mL, and 36.2 pg/
mL, respectively). CSF-NfL levels showed a significant cor-
relation with NfL levels in serum. In this study, blood NfL
levels of patients were robust, independent predictors of
survival.
Parkinson’s Disease
Parkinson’s disease (PD) is the second most frequent neuro-
degenerative disease after AD [38]. PD is a movement disor-
der characterized by the progressive loss of dopaminergic
neurons in the substantia nigra. The etiology of the disease
is unknown but mutations in α-synnuclein have been found in
rare cases of familial PD [39]. The prevalence of the disease is
about 1% of the population older than 60 years of age, and the
mean age of onset is estimated to be the early to mid-60s. The
clinical manifestation of PD is principally motor dysfunction
including involuntary tremor, bradykinesia, and rigidity [40].
It has been found that the symptoms and motor signs of PD
are due to the degeneration of large parts of the substantia
nigra (SN). PD is associated with the degeneration of multiple
neurotransmitter systems (e.g., serotonin, noradrenaline, ace-
tylcholine) [41] which are linked to non-motor diseases and
can also impact cognitive function [42].
The most important challenge is differential diagnosis be-
tween PD and atypical Parkinsonian disorders (APD), includ-
ing multiple system atrophy (MSA), progressive supranuclear
palsy (PSP), and corticobasal degeneration (CBD). Reliable
Fig. 1 A schematic of different
types of Nfs and their detection in
CNS related disorders. Nfs act as
neurotransmitter. These
neurotransmitters are categorized
based on their molecular weight.
Different types of Nfs could be
released in the CSF, serum, and
plasma. When an injury occurred,
increased levels of Nfs will
release in various body fluids
includingCSF, serum, and plasma
which could be detected by
various techniques such as
ELISA. NfL, NF light; NfM, NF
medium; NfH, NF heavy; ELISA,
enzyme-linked immunosorbent
assay
Fig. 2 A schematic
representation of normal and ALS
nerve cell. Injured motor neurons
in the spinal cord and brain are
ALS pathogenesis characteristic.
The degenerated neurons are not
capable of sending the impulses
crucial for movement to the
muscle fibers
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differentiation of PD fromAPD is often problematic due to the
overlapping symptoms, especially during the early stages of
the disease development [43, 44].
Although there is no established biomarker for PD diagno-
sis [38], NfL protein in CSF may be a promising biomarker to
distinguish PD from other similar diseases. The increased NfL
levels in CSF could reflect the degree of neuronal cell apopto-
sis partly due to microglia-mediated inflammation [45]. It has
been shown that the CSF concentration of NfL is increased in
APD compared to PD [38, 46], and that NfL levels in CSF can
distinguish PD from MSA with a high degree of diagnostic
accuracy, for instance, a 17.5 ng/L cutoff point gave high
sensitivity (76–94%) and specificity (83–97%) [47].
The relation between PD disease severity and CSF-NfL
levels is still controversial. While one study demonstrated that
higher levels of NfL in CSF were associated with more severe
PD, [48], a similar study claimed that although the NfL con-
centration was elevated in PD patients when compared to the
normal group, there was no correlation between NfL levels
and disease severity in PD patients [49]. Furthermore, there
was no specificity with respect to the increase of NfL concen-
tration. Interestingly, in that study, a positive correlation was
found between CSF-NfL levels and VEGF [49].
In addition to CSF-NfL, blood-based NfL levels can be
used to discriminate PD fromAPD. Several studies have dem-
onstrated that, comparing PD and other diseases with healthy
controls, blood-based NfL concentrations were increased in
PSP, MSA, and CBD patients [46, 47]. For example,
Hansson et al. showed that blood NfL levels discriminated
PD from APD in patients during the onset phase with 80%
specificity and 70% sensitivity [46]. Therefore, blood-based
NfL assays might be considered as a diagnostic biomarker in
PD patients receiving primary care as well as in dedicated
clinics [46].
Multiple Sclerosis
MS is a demyelinating autoimmune disease usually character-
ized by relapsing periods of neurological dysfunction. MS is
the major cause of neurological disability among young
adults. The onset of MS is usually followed several years later
by progressive and permanent deterioration [50–54].
Axonal loss is one pathological element responsible for the
progressive disability in both primary progressive and
relapsing-remitting MS, so finding a diagnostic biomarker to
detect and quantify MS is of great importance [55]. NfL pro-
tein released into both CSF and blood in patients with MS
could be a promising biomarker of disease activity, as well
as other neurodegenerative diseases [53, 55, 56].
Researchers have demonstrated that CSF-NfL is increased
in both relapsing-remitting and primary progressive MS, and
CSF levels could be considered as a predictive biomarker of
long-term disease outcome [53, 54, 56–58]. It is important to
bear in mind that a cutoff value of CSF-NfL was considered
900 ng/L based on several previous studies [59–61]. These
studies indicate that the CSF-NfL concentration is related to
continuing axonal injury and mirrors the severity of the pro-
cess. Therefore, CSF-NfL could be a promising biomarker for
disease severity and progression, as well as for treatment as-
sessment [62].
In addition to CSF-NfL, the potential value of serum NfL
has been demonstrated as a biomarker of neuroaxonal injury
in early MS [58, 63]. Kuhle et al. found that there was a
relationship between baseline serum NfL and whole brain
atrophy, disability, and cognitive impairment [63] which sup-
ports the idea of the value of serum NfL as a noninvasive
prognostic biomarker of the overall outcome of brain damage
and continuing disease activity in early MS. The correlation
between CSF-NfL and serum NfL has been investigated in
several studies [56, 58]. Novakova et al. found that the corre-
lation between serum and CSF-NfL levels was 0.62 in MS
patients. For CSF-NfL, they found 75% specificity and 67%
sensitivity, while serum NfL had 80% specificity and 45%
sensitivity. In this study, serum NfL concentrations were con-
siderably higher in patients with relapsing-remitting MS
(16.9 ng/L) and in patients with progressive MS (23 ng/L)
when compared to the healthy control group (10.5 ng/L)
[56]. The calculated cutoff value of serum NfL in this study
was 18.2 ng/L. While there is no common agreement on the
relationship between CSF-NfL levels and age or gender
[64–66], some studies have shown significant associations
with age in both controls or patients [67, 68].
As an overall conclusion, NfL levels in CSF or serum ap-
pear to be a sensitive and specific biomarker for white matter
axonal damage in the CNS of MS patients with a significant
relationship to disease severity and progression [58].
Alzheimer’s Disease
AD is a common neurodegenerative disease that affects the
cerebral cortex. The incidence increases with age, and about
30% of AD patients are above 85 years old [69]. The etiology
of AD is not completely clear. Extracellular deposition of ag-
gregated Aβ into amyloid plaques and intraneuronal accumu-
lation of neurofibrillary tau protein tangles are the considered
to be the canonical pathophysiological hallmarks of AD. It is
commonly believed that neurons that are injured by neurofi-
brillary tangles, amyloid plaques, or other causes undergo
breaks in the interneuronal connections. These synaptic breaks
contribute to damage in the brain regions associated with cog-
nition and memory (Fig. 3) [70]. The abnormality of the cy-
toskeletal proteins observed in AD patients is closely connect-
ed to the pathology of AD [69]. In addition to loss of cortical
and hippocampal neurons and graymatter degeneration which
are the principal features, progressive disconnection of corti-
cal and subcortical regions due to disruption of white matter
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(WM) may be found in AD patients. WM atrophy can be
demonstrated in tracts which are composed of large-caliber
myelinated axons such as the corpus callosum and in key
regions such as the cingulum, which are rich in Nfs [71].
The brain changes in AD commence decades before the
diagnosis of any disease [72]. Therefore, finding a noninva-
sive prognostic biomarker and testing potential early treatment
options to prevent Alzheimer’s disease prior to the onset of
symptoms are of great importance [73]. Several studies have
assessed the level of CSF-NfL in AD patients [71, 73, 74].
Zetterberg et al. found that there was a significant correlation
between CSF-NfL concentration and cognitive decline in AD
patients. It was shown that CSF-NfL levels were higher in a
AD dementia group as well as in a stable mild cognitive im-
pairment (MCI) group, and in a progressive MCI group com-
pared to a healthy control group. They also demostrated that
CSF-NfL level was higher in AD dementia patients (mean
1479; 1134–1842 pg/mL), compared with the stable MCI
group (mean 1182; 923–1687 pg/mL) and progressive MCI
group (mean 1336; 1061–1693 pg/mL). A higher CSF-NfL
concentration was shown to be correlated with more rapid
progression of brain atrophy over time, and it was associated
with changes in the volume of the whole brain, ventricular,
and hippocampal regions [71].
In a similar sudy, it was shown that CSF-NfL could poten-
tially discriminate AD pathophysiology-positive patients from
a healthy control group, while the ability to segregate tau-
positive patients from the healthy control group was only fair.
It was also shown that CSF-NfL was not a satisfactory marker
to distinguish AD pathophysiology-positive patients from
FTD patients [75].
Blood-based NfL levels have also been evaluated in AD
[72, 73]. It was confirmed that concentrations of plasma NfL
in patients with AD could be distinguished from healthy con-
trols at a cutoff value of 25.7 pg/mL [72]. The values of ab-
solute sensitivity, specificity, and accuracy were 84%, 78%,
and 82%, respectively.
Similarly, serum NfL levels have been analyzed in a study
to distinct familial AD (FAD) from healthy controls. This
study found that the serum NfL levels were amplified in
FAD patients before symptom onset and correlated with dis-
ease stage and severity [73].
To summarize, fluid-based NfL assays may be a useful
biomarker of AD-related neurodegeneration prior to symptom
onset.
Frontotemporal Dementia
FTD describes a diverse spectrum of neurodegenerative dis-
orders primarily affecting the frontal and temporal lobes [76].
The major causes of genetic FTD are mutations in the genes
that encode microtubule-associated protein tau (MAPT),
progranulin (GRN), or chromosome 9 open reading frame 72
(C9orf72). Mutations in the C9orf72, GRN, andMAPT genes
have been detected in 60% of familial FTD patients. C9orf72
mutations account for 25% of these and are the most preva-
lent. Rarer mutations (< 5%) take place in other genes includ-
ing TBP, TBK1, ITM2B, FUS, TARDP, CHMP2B, and VPC
[76–78].
Behavioral variant FTD (bvFTD), semantic dementia (SD),
and progressive non-fluent aphasia (PNFA) are the principal
clinical subtypes of FTD [79, 80]. The clinicopathologic char-
acteristics of corticobasal degeneration (CBD) and progres-
sive supranuclear palsy (PSP) overlap with those of FTD.
The main challenge in the diagnosis of FTD is determining
the precise neuropathological subtype, based on clinical fea-
tures alone. Although fluid biomarkers might aid in diagnos-
ing disease onset and assessing disease-modifying treatments
for FTD, few have as yet been investigated. Among CSF
biomarkers for FTD, NfL has been recently assessed in several
studies [13, 76–78, 81]. While several early studies showed
variability in CSF-NfL concentrations in FTD [82–84], others
have claimed that CSF-NfL levels correlated with disease se-
verity [81]. NfL levels in the CSF have been demonstrated to
be increased in FTD (and in other neurodegenerative disorders
like ALS, AD, PD, and MS) [82–87]. By contrast, a small
series of presymptomatic individuals carrying FTD-causing
mutations have been found to have low levels of CSF-NfL
[81]. In one study, the patients with neuropathologically ver-
ified FTD (although a limited number of cases) had NfL
values that were significantly higher in the tau-negative cases
(median 1620 ng/L) compared with the tau-positive cases
(median 665 ng/L). This study found no association between
the levels of NfL and the severity of cortical degeneration
[77]. Some studies have reported higher CSF-NfL levels in
FTD patients, compared with both early-onset AD patients
and a healthy control group [13]. Furthermore, it has been
shown that the higher levels of NfL were correlated to shorter
survival times in patients [77, 78, 88]. For example, higher
CSF-NfL levels could distinguish patients from controls,
using a cutoff level of 2165 pg/mL with sensitivity of 84%
and specificity of 100% [78]. Similar to other degenerative
diseases mentioned above, serum NfL levels have been inves-
tigated in several studies looking at biomarkers for FTD [78,
88]. Serum NfL concentrations were shown to be correlated
with CSF-NfL levels and were higher in FTD patients (mean
77.9 pg/mL) compared to controls (19.6 pg/mL). In addition,
serum NfL levels were considerably higher in FTD patients
(57.8 pg/mL) and in both the non-fluent and semantic variants
of PPA (82.5 and 95.9 pg/mL, respectively) compared to nor-
mal controls. Moreover, serum NfL concentrations were
higher in patients with semantic variant of PPA compared to
the logopenic variant of PPA [88].
Similar to the previous study, levels of serum NFL were
significantly higher in the C9orf72 mutation as well as the
MAPTsubgroups (79.2 pg/mL and 40.5 pg/mL, respectively).
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Compared to these two latter subgroups, the GRN-mutated
group had even higher concentrations of serum NfL
(138.5 pg/mL) [78].
Overall, both CSF and serum NfL levels could potentially
serve as a valuable biomarker for clinical disease diagnosis
and have a predictive value in genetic FTD [78, 88].
Stroke
Elevated Nf levels in CSF after subarachnoid hemorrhage
represent the most convincing evidence that NfL analysis
could be useful in stroke. Investigations have revealed that
both NfL and NfH concentrations are increased in individuals
with aneurysmal subarachnoid hemorrhage compared to pa-
tients with no neurological disease or to healthy controls [68,
89, 90]. In the absence of related focal injuries, the main
mechanisms of Nf liberation in subarachnoid hemorrhage (is-
chemia due to vasospasm or parenchymal haematoma) are not
completely obvious, but they could be connected to diffuse
neuroaxonal damage or could possibly be iatrogenic, for in-
stance caused by placement of an external ventricular drain. A
recent report suggested that raised Nf concentrations could be
related to the extent and severity of morphological brain injury
in stroke [89]. The evaluation of NfL levels in stroke by uti-
lizing fourth-generation immunoassays to analyze NfL con-
centrations in blood samples has been reported; however,
there is usually no clinical indication for a lumbar puncture,
so CSF analysis is not common. NfL serum levels were great-
er in spontaneous cervical artery dissection patients undergo-
ing an ischemic stroke, than among transient ischemic attack
subjects or those with isolated local symptoms [91]. Likewise,
serum levels of NfL were found to be increased in affected
individuals with a single, recent, small subcortical infarct in
comparison to the levels in sex-matched and age-matched
healthy subjects [92]. Furthermore, temporal dynamic evalu-
ation of NfL levels at 3 and 15 months post-stroke showed
particularly high concentrations in patients with new, clinical-
ly silent brain injuries associated with small vessel disease that
has been detected using magnetic resonance imaging (MRI)
during follow-up. This observation suggests that increased
levels of NfL are indicative of active small vessel disease.
Also, during the first few days after stroke onset, serum levels
of NfL were increased and remained elevated at a 3-month
follow-up assessment. Other investigations have documented
similar findings of changes in Nf dynamics [58, 93]. After
acute neuronal injury, prolonged NfL release into the blood
may be caused by persistent breakdown of the blood–brain
barrier, but continuing post-ischemic inflammatory or immu-
nological cascades could also be responsible.
Huntington’s Disease
Huntington’s disease (HD) is a progressive neurodegenerative
disorder, caused by repeated expression of CAG segments in
Fig. 3 A schematic showing different events in the pathogenesis of
Alzheimer’s disease. An alteration in tau protein leads to microtubule
breakdown in brain cells. A healthy neuron and an affected neuron are
shown. Tau phosphorylation contributes to the formation of
neurofibrillary tangles in Alzheimer’s disease. In patients with
Alzheimer’s disease, hyperphosphorylation of specific amino acids in
the tau protein leads to the proteins dissociating from the microtubules
and forming tau tangles. At the same time, extracellular amyloid plaque
disturbs the transport structure and leads to the starvation of neurons, and
ultimately induces cell death
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the HTT gene, resulting in formation of mutant huntingtin
protein.
HD commonly causes psychiatric, cognitive, and move-
ment disorders with a wide variety of signs and symptoms
[94]. Recent investigations have proposed that in HD, the
main pathogenic factor is the production of ubiquitinated
aggregates of the N-terminal fragment of the mutated
huntingtin protein. This aggregation is supposed to take
place because of increased cleavage of the polyglutamine-
rich part of the mutant huntingtin N-terminus [95].
Aggregates of the mutant protein have been found in the
striatum, hippocampus, pyramidal neurons, subiculum, en-
torhinal cortex, and neocortex, especially in the case of ju-
venile and advanced onset HD patients. Neuropathological
studies have shown that HD brain abnormalities probably
commence well prior to the emergence of symptoms, and
finally progress to affect the whole brain to a greater or lesser
extent, leading to an approximately 25% loss of total brain
weight in advanced HD [96]. However, gross atrophy occur-
ring within the striatal part of the basal ganglia, accompanied
by astrogliosis and extensive neuronal loss, is the most no-
ticeable neuropathological finding. These changes become
more severe as the disease progresses, with the atrophy
resulting in excessive enlargement of the lateral ventricles
[97].
Studies in biomarkers for HD have suggested that changes
in glutamic acid decarboxylase (GAD) or receptors for neu-
ropeptides can be found in striatal neurons and their termi-
nals. For instance, grade 0 HD has been characterized by loss
of adenosine receptor (A2a), dopamine receptor (D2), and
cannabinoid receptor in the striatum, as well as large eleva-
tion in γ-amino-butyric acid A (GABAA) binding in exter-
nal pallidal segments (GPe) [98]. These findings are consis-
tent with the preferential loss of enkephalin-containing
(ENK+) input to the GPe in grade 0 HD. The absence of
any decrease in D1 receptor binding in the internal pallidal
segments (GPi) or the striatum in grade 0 HD suggests that
striatal substance P-containing (SP+) neurons, especially
those projecting to the GPi, are mostly unaffected in pre-
symptomatic HD [98].
No proven disease-modifying therapies for HD have yet
been discovered [99]. In HD, the insidious and slow develop-
ment of symptoms has made it challenging to detect disease-
associated alterations in Nf proteins levels in blood [100].
However, elevated CSF concentrations of NfL have been re-
ported in HD patients (control vs disease 51.6 pg/mL and
432.4 pg/mL, respectively) [101, 102], and fourth-generation
technology has shown a good correlation betweenNfL plasma
levels and HD onset, and the neurodegeneration progression
(cutoff 31·7 pg/mL) [99]. Therefore, to determine its useful-
ness as a diagnostic or prognostic biomarker in HD, NfL
levels in blood should be considered in future investigations
and clinical trials.
Bipolar Disorder
Bipolar disorder (BD) is a chronic psychiatric disorder
characterized by mood swings between manic and depres-
sive states. BD affects 1–3% of the population, entails
high costs for society, and is associated with great person-
al suffering, functional impairment, premature mortality,
and a higher risk for other psychiatric and medical disor-
ders [103]. It has been suggested that neuroaxonal injury
and neurodegeneration could be related to BD [104].
Although neuroaxonal injury is not considered to be typ-
ical of BD, CSF concentrations of NfL were elevated in
patients with BD (control vs disease 359 pg/mL and
480 pg/mL) [103]. However, no significant correlation
was shown between clinical outcomes and NfL concen-
trations, including suicide attempts, hypomanic or manic
and depressive episodes, inpatient care, or psychotic
symptoms (cutoff <395 pg/mL) [105]. Although the avail-
able data that neuroaxonal damage could be assessed in
BD by Nf assays are limited, the current evidence war-
rants longitudinal investigations of well-diagnosed pa-
tients to test how Nf levels are altered in relation to dis-
ease phase (mania and depression), as well as whether Nfs
are influenced by the adverse effects of therapies such as
long-term lithium administration [106].
Spinal Cord Injury
Acute spinal cord injuries (SCI) are some of the most
devastating accidents affecting young and active individ-
uals. Mechanical injury of the spinal cord results in
damage to neurons, axons, and glia at the area of im-
pact [93]. Much effort has been put into the evaluation
of SCI severity and prediction of recovery potential in
affected individuals. Interventions designed to encourage
the recovery of function following SCI include a com-
bination of pharmacological, surgical, and rehabilitation
approaches. The benefits of these interventions, howev-
er, have been somewhat equivocal in clinical trials. It is
assumed that patients with more severe SCIs respond
differently to neuroprotective interventions than do pa-
tients with less severe SCIs. An accurate assessment of
the initial extent of damage to the spinal cord that could
differentiate between different severities of SCI may
help physicians to choose a conventional treatment or
explore experimental neuroprotective intervention in the
acute phase [107]. Serum NfL may represent a useful
indicator of SCI severity and the long-term outcome of
neuronal injury, especially in cases where accurate clin-
ical assessment is not possible. Further studies are war-
ranted to assess the evidence for NfL as a treatment
response marker in SCI [93].
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Charcot–Marie–Tooth
Charcot–Marie–Tooth (CMT) disease is genetically and clini-
cally heterogeneous. A large number of disease-causing muta-
tions in several genes have been described. CMT is a neuro-
muscular disease characterized by length-dependent and pro-
gressive degeneration of peripheral nerves, manifesting with
muscle wasting and weakness in the hands, feet, and distal
limbs. Its clinical severity ranges from mild to severe, and its
onset can vary from childhood to adulthood in affected subjects.
The neuropathological and neurophysiological impairments in
the sensory and motor nerves contribute to the sensory deficits,
wheelchair dependence, walking disabilities, and foot deformi-
ties. Recently, genetic and clinical investigations have sug-
gested that CMT is quite heterogeneous. In the 1970s, a classi-
fication was suggested dividing the most prevalent CMT vari-
ants, as hereditary, sensory, and motor neuropathies. In CMT1,
the Schwann cells are affected, while in CMT2, the axons un-
dergo degeneration. Besides, these two inherited autosomal
dominant CMTsubtypes, axonal as well as X-linked and reces-
sive demyelinating subtypes of CMT, have been recognized
and are included in the mentioned classification [108]. Based
on the severity of the sensory or motor deficits, other CMT
subtypes have been categorized into hereditary sensory and
autonomic neuropathies and distal hereditary motor neuropa-
thies [108]. Overlaps in both genetic analysis and clinical symp-
toms have been recently shown between hereditary spastic
paraplegias and CMT neuropathies. Furthermore, some patients
have more complex clinical phenotypes involving other tissues,
including bone and skin [109, 110].
Six pathogenic missense mutations and one 3-bp in-frame
deletion in the NfL gene have been found in 323 patients with
different CMT phenotypes. Mutations predominantly
resulting in demyelination may cause concomitant axonal
loss, and mutations primarily leading to axonal loss may be
associatedwith demyelination.Mutations in the NfL gene also
result in CMT neuropathies with variable clinical and electro-
physiological characteristics. NfL mutations should be con-
sidered in the evaluation of patients with CMTor related neu-
ropathy [111]. Nonsense NfL mutations probably cause a re-
cessive phenotype, in contrast to missense mutations that
cause a dominant phenotype in patients with CMT [12].
In one study, Sandelius et al. measured the plasma level of
NfL in 142 subject (75 CMTsubjects and 67 healthy subjects)
and its relationship with disease severity [112]. Their results
showed that the plasma levels of NfL were significantly
higher in CMT subjects (median 26.0 pg/mL) compared to
healthy subjects (median 14.6 pg/mL). Moreover, the plasma
levels of NfL were correlated with neuropathy scores and
disease severity. They reported that the subjects with different
genetic subtypes including SPTLC1, CMT1A, and GJB1 had
significantly higher levels of NfL compared to healthy sub-
jects [112].
Assays to Detect Soluble Neurofilaments
The sensitivity of immunoassay technologies has in-
creased remarkably during the past three decades.
Likewise, the detection of neurofilament biomarkers has
also advanced, moving toward more clinically relevant
applications (Fig. 4). First-generation immunoassays were
only semi-quantitative in nature. Methods such as immu-
noblots, which are based on electrophoretic protein sepa-
ration, or dot blots were able to show only the presence of
neurofilament isoforms in the blood and CSF of subjects
suffering from a range of diseases [113]. Second-
generation sandwich ELISA technologies created the first
trustworthy quantitative assays that enabled evaluation of
the diagnostic and prognostic value of NfL and NfH de-
terminations in the CSF of patients [60, 114]. Human
body fluids were analyzed with this method, expanded
to include the vitreous fluid, amniotic fluid, plasma, and
serum, together with extracellular or interstitial fluid [115,
116].
International studies for validation and meta-analyses
have found that high accuracy could be achieved in expert
laboratories, but they also emphasized the requirement for
standardization of the assays [117]. A considerable improve-
ment in analytical sensitivity was achieved in third-
generation ECL technology. ECL-based assays are recog-
nized to require only a low sample volume, can have a broad
dynamic range, and be highly sensitive. However, fourth-
generation bead-based technology (SiMoA) is even more
sensitive: 25-fold more sensitive than ECL and 126-fold
more than ELISA methods [118]. Therefore, the analytical
sensitivity has steadily improved over time, leading to the
reliable quantification of NfL levels in blood becoming pos-
sible for the wide range of levels found in both physiological
conditions and in diseases [119]. The cutting-edge SiMoA
technique is based on the simultaneous counting of individ-
ual microscopic beads with capture antibodies (2.7 μm di-
ameter) and single-molecule arrays that work via sandwich
antibody technology (one antigen recognized by two anti-
bodies). The analytical sensitivity is many fold higher than
that achieved using the same antibodies in an ELISA format,
and can reliably measure the low NfL levels that are present
in young healthy subjects, so that minor changes in concen-
trations of NfL that occur during normal aging or after mild
injury could be detected [120]. A close relationship between
concentrations of NfL in the CSF and concentrations in the
plasma or serum has been established in several studies on
individuals with different neurological disorders. This rela-
tionship permits measurements to be made on blood samples
without any requirement to obtain CSF using lumbar punc-
ture [121]. Studies of NfM have been sparse, but commercial
SiMoA kits for the measurement of phosphorylated NfH as
well as NfL are now available [122].
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Magnetic Resonance Imaging
and CNS-Related Disorders
The prognosis and diagnosis of CNS-related disorders can be
achieved by combining both biomarkers and a neuroimaging
approach [123]. Although the early diagnosis of CNS-related
disorders is possible with the aid of various neuroimaging
methods, there is a need for gold standard in this context.
Accordingly, it may be possible to screen individuals at high
risk for neurological disorders and to test novel neuroprotec-
tive agents in such populations, aiming at the management of
disease progression and the discovery of new disease-
modifying interventions [124].
Magnetic resonance imaging (MRI) is a noninvasive
neuroimaging approach to provide indices useful in the
diagnosis and prognosis of CNS-related disorders [34].
Visual scoring, local morphometry, and volumetric analy-
ses are the principles behind structural MRI evaluation of
different CNS-related disorders. The available guidelines
are not only non-specific for accurately differentiating
neurodegenerative diseases, but also require experienced
clinical expertise and include a certain degree of subjec-
tive assessment. Automatic image quantification and com-
puterized support for decisions are able to provide more
information, than simple examination of images with the
human eye, in order to differentiate the target disease
from other neurodegenerative diseases, and may offer
support for inexperienced clinicians [124].
Besides structural (anatomical) MRI, diffusion tensor im-
aging (DTI-MRI) can assess diffusivity (reflecting microstruc-
tural damage) and fractional anisotropy (reflecting white mat-
ter tract integrity), and may provide a higher degree of sensi-
tivity and specificity. DTI is based on the measurement of “the
random motion of water molecules in fluid water” [125].
Diffusion of water molecules is not identical in different struc-
tures of the brain. For example, water molecules move more
easily along axonal bundles of white matter, resulting in an-
isotropic diffusion. In contrast, diffusion usually is isotropic in
the gray matter because it does not possess a clear structural
arrangement. This diffusion property of water can be used as a
quantitative tool to interpret the brain anatomy [126]. It has
many advantages to study the integrity and orientation of
white matter in both normal and pathological states [127].
Mean diffusivity (MD) and fractional anisotropy are two fun-
damental metrics in DTI. MD illustrates the diffusion of water
molecules in a biological tissue [128]. Also, values of frac-
tional anisotropy (FA), radial diffusivity (RD), and axial dif-
fusivity (AxD) are characteristic of white matter alteration in
the brain. While decreased FA is a frequent observation in
brain tissue injury, RD is a measure of diffusion perpendicular
to the axons and is therefore commonly associated with the
microstructure of myelin [127].
Fig. 4 The release of Nf after axonal injury. When an axon is injured,
cytoskeletal proteins, such as neurofilaments, are released into the
cerebrospinal fluid and, at lower levels, into the blood. First-generation
(immunoblots) and second-generation (ELISA) immunoassays can mea-
sure neurofilaments in the CSF but have low sensitivity for detecting in
the blood. Third-generation (electrochemiluminescence) and fourth-
generation (single-molecule array) methods can detect blood concentra-
tions of neurofilament light and measure subtle longitudinal alterations in
healthy controls and in pathological cases
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Various studies have established that NfL and MRI indices
might be considered as promising biomarkers for diagnosis or
prediction of disease development in different neurological
disorders. Several studies have been carried out to relate these
two biomarkers directly in many common neurodegenerative
diseases. It will be a major improvement if scientists can com-
bine NfL with MRI measures and identify the type and loca-
tion of neurodegeneration before any clinical presentation of
symptoms.
Correlation of MRI Parameters and NFL
Amyotrophic Lateral Sclerosis
Combining biological biomarkers with neuroimaging bio-
markers is critical in diagnosing and monitoring neurodegen-
erative disease [129, 130]. Researchers have put much effort
into investigating the correlation of CSF and/or blood-based
biomarkers such as NfL, with DTI imaging in ALS. In one
study, CSF and serumNfL concentrations combined with DTI
using a 3T MRI machine with 12 head coils were analyzed. It
was found that NfL levels had a negative correlation with FA
and a positive correlation with RD in the DTI of the
corticospinal tract (CST) of ALS patients when compared to
controls. The positive correlation between RD and NfL levels
could be explained by the sensitivity of RD to Wallerian-type
myelin degeneration found in ALS. In contrast, no association
between NfL levels and AxD was observed [129].
Degeneration of the CST in ALS results in alteration of
NfL levels and DTI markers. Therefore, it can be concluded
that longitudinal DTI analysis of white matter changes is a
noninvasive and quantitative biomarker that can be combined
with NfL levels as a more robust method to monitor neurode-
generation, which correlates with clinical progression in ALS
[129, 130].
One study reported the correlation of CSF-NfL with FA
and different DTI metrics (MD, RD). The changes in FA
and RD were sensitive to loss of axonal integrity, demyelin-
ation, and Wallerian-type myelin degeneration, especially in
chronic diseases with pronounced axonal damage [131].
Evidence suggests a relationship between MD alterations
and changes in cellularity, probably due to myelinated axonal
loss [132, 133]. The findings should be interpreted cautiously,
because of the uncertain biological basis of the differences in
DTI variables, particularly for pathological comorbidities, in-
cluding axonal damage, demyelination, and inflammation
[131]. These results are consistent with studies that reported
the relationship between higher CSF-NfL levels and altered
DTI metrics in ALS [134, 135]. However, they are inconsis-
tent with another ALS study that found no relationship be-
tween DTI CST integrity and CSF-NfL [134]. Steinacker
et al. scanned patients using two different MRI systems with
two different field strengths (two thirds with a 1.5T MRI, and
one third with a 3T MRI). Their results showed comparable
data from the two systems; therefore, all the DTI values were
combined in a single analysis. The 1.5T field strength gave a
signal-to-noise ratio lower than the 3T field strength, poten-
tially masking the relationship between FA values and NfL
levels [134]. Menke et al. [23] found a relationship between
NfL levels and both FA and RD values in ALS patients using
data from a single 3T scanner with a protocol similar to the
Steinacker study. This field strength may be able to increase
the study sensitivity to detect the effects masked by noise.
Contradictory results were reported by another study,
which found no relationship between serum NFL levels and
ALS pathological stage using DTI for assessing the integrity
of brain white matter tracts [136]. There are reports on the
relationship between CSF-Nfs and damage caused to upper
or lower motor neurons in different parts of the body, as well
as between CSF-NfL levels and MRI markers of corticospinal
tract degeneration [14, 23].
Multiple Sclerosis
The CSF or serum NfL levels have been investigated as bio-
markers along with MRI of lesions to assess relapses, neuro-
logical disability, and treatment methods in MS [137].
The annual serum NfL levels were measured to predict 10-
year clinical progress and MRI findings in MS patients, using
a brain MRI acquisition protocol on a 3T unit with three sag-
ittal sequences of 3D T1-weighted gradient echo, 3D T2 spin
echo, and 3D T2-FLAIR. The evaluation of the relationship
between NfL levels and 10 years of measurement of brain
parenchymal fraction (BPF) exhibited an inverse relationship
between year 5 NfL levels and year 10 BPF. There were sta-
tistically significant relationships between averaged annual
NfL values and year 10 BPF. The evaluation of relationship
between NfL levels and year 10 T2LV revealed a positive
relationship between years 1–4 with T2LV, highlighting the
relationship between higher NfL levels and more severe brain
lesions. According to the results from this study, there was a
relationship between both early and averaged annual serum
NfL levels, and 10-year MRI findings and worsening fatigue.
The relationship between early NfL levels and long-term pro-
gression suggests the necessity for predictive models to detect
patients at risk for more severe disease [137].
One study examined baseline and annual brain MRI scans
(T1w MPRAGE and T2w lesion) on patients using a 1.5T
magnetic resonance scanner [138]. The relationship between
serum NfL levels and brain MRI findings was evaluated to
compare disease activity and normalized brain volume. The
results showed that the serumNfLwas enhanced with increas-
ing lesion size and was related to all the MRI metrics. The
multivariable model exhibited a relationship between each
contrast-enhancing lesion and increased serum NfL levels.
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There was a relationship between smaller normalized brain
volume and higher serum NfL levels. However, the multivar-
iable analysis showed no relationship between NfL and T2
lesion volume. They suggested the increased serumNfL levels
were caused by focal active inflammation, which was mea-
sured by brain contrast-enhancing lesions and enlarging T2
lesions. There was a strong relationship between the serum
NfL levels and the number of T2 lesions, which are a more
comprehensive marker of brain lesion burden, suggesting the
serum NfL could be used to detect the extent of brain injury in
individual patients. The findings also underlined the relation-
ship between serum NfL levels and the normalized brain vol-
ume at the time of sampling. They concluded that the serum
NfL levels could be used as a quantitative marker for the
extent of neuronal loss in the CNS [138].
AD and FTD
In one study, Weston et al. carried out MRI in AD patients on
the same 3T Siemens scanner, while also taking blood sam-
ples; they used sagittal 3D magnetization-prepared rapid gra-
dient echo (mparage) T1-weighted volumetric MRI that
allowed calculation of whole brain, ventricular, and hippo-
campal volumes [139]. They also computed the annual rate
of changes in brain, ventricular, and hippocampal volumes
over the interscan intervals, as well as exploring a relationship
between NfL and MRI findings to measure AD-related neu-
rodegeneration. Their results revealed a relationship between
serum NfL levels and MRI findings for cross-sectional vol-
ume loss and atrophy, indicating a relationship between serum
NfL levels and AD severity or progression rate [139].
A similar study carried out 3D-SPGR T1-WI cortical re-
construction and volumetric segmentation on a 3.0T MRI
scanner and measured the cortical thickness of AD and FTD
patients in different anatomical regions in comparison with
controls [140]. They studied the hippocampus, parietal, and
frontal lobes in the AD group and superior frontal, orbito-
frontal, caudal middle frontal, rostral middle frontal, inferior,
and superior parietal lobes in the FTD group. The differences
in cortical thickness between patients and controls were cal-
culated in accordance with an equation. The assumption was a
priori, so that the cortical thickness was lower in the patients
compared to the control. Their results revealed a marginal
inverse correlation between NfL levels and left orbito-frontal
cortical thickness in the FTD group. This biological finding,
although not statistically significant, confirmed the relation-
ship between elevated NfL levels and increased left frontal
lobe atrophy in the patients suffering from semantic variant
primary progressive aphasia (svPPA) and non-fluent variant
primary progressive aphasia (nfvPPA) but not from lvPPA23.
According to studies conducted on genetic FTD, NfL levels
showed an inverse correlation with whole brain volume and
with the volume of frontal, temporal, parietal, insular, and
cingulate cortices [140].
In another study, Rohrer et al. carried out volumetric T1
brain MRI on a 3T scanner in patients with FTD on the same
day as serum sampling, over a maximum of 6 months. They
measured whole brain and individual lobar cortical volumes
[141]. The difference in volume between the baseline and
follow-up scans was used to compute annualized lobar atro-
phy. The relationship between serum NfL levels and the cog-
nitive and imaging parameters was assessed by Pearson’s cor-
relation coefficient. No significant correlation was found with
baseline brain volumes. There was a correlation between the
serum NfL levels and rates of whole brain, frontal lobe, and
parietal lobe atrophy, but not between the serum NfL levels
and other lobar atrophy rates. The correlation with frontal lobe
atrophy was corrected for multiple comparisons. According to
their results, the serum NfL levels showed a relationship be-
tween the extent of subsequent brain atrophy, but not with the
baseline brain volumes. The brain atrophy parameters are
probably more suitable for the detection of disease severity
when compared with the cross-sectional index of the whole
brain or lobar volumes, reflecting disease duration and illness
severity. There was a relationship between serum NfL levels
and baseline indices of executive function, but not between
serum NfL levels and longitudinal indices [141].
White matter damage in FTD was investigated using DTI-
MRI analysis in several studies. Decreased FA and increased
MD in the white matter were common findings in these stud-
ies in FTD patients [142–144]. One study found that FAwas
increased and MD was decreased within the body of the cor-
pus callosum, bilateral cingulum bundle, and bilateral unci-
nate fasciculus [145]. NfL levels in CSF or serum have been
investigated as a potential biomarker in predicting neurode-
generation in FTD [82–86]. Up to now, we have found only
one study comparing white matter damage in FTD using NfL
measures and DTI indices in which FA, MD, AD, and RD
were measured [146]. In that study, twenty white matter tracts
were analyzed based on tract-specific correlation. In the
fronto-posterior tracts, a positive correlation was found be-
tween NfL measures and MD, AD, and particularly with
RD, and a negative relationship with FA was observed in
frontal regions. There were no correlations found in C9orf72
carriers [146]. It was concluded that combining NfL levels
and DTImeasures together resulted better monitoring of white
matter damage in FTD [146].
Stroke
Studies have investigated correlations between NfL levels and
cerebral small vessel disease (SVD), which is a leading cause
of stroke and vascular cognitive dysfunction. One study ex-
amined patients with SVD using a single 3T/1.5T MRI scan-
ner with a standardized protocol, consisting of 3D-T1,
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FLAIR, T2, and DTI sequences [147]. White matter
hyperintensity (WMH), lacunae, brain volumes, and the num-
ber of cerebral microbleeds were measured in this study,
followed by evaluation of relationships between the serum
NfL levels and established MRI markers for SVD, corrected
for age and sex. According to a simple linear regression mod-
el, there was a significant relationship between serum NfL
levels and all the MRI markers, as well as age in the patients
with CADASIL (cerebral autosomal dominant arteriopathy
with subcortical infarcts and leukoencephalopathy), and spo-
radic SVD. The most significant correlation was with mean
diffusivity in SVD patients. A significant relationship was
found after controlling for age. There was a relationship be-
tween the serum NfL levels and MRI, as well as with clinical
features in hereditary and sporadic SVD, thereby verifying the
use of MRI to assess SVD severity [147].
Another study investigated the temporal characteristics of
serum NfL levels and its relationship with MRI findings of
neuroaxonal injury and with clinical outcomes [148]. There
was a relationship between 6-month post-stroke serum NfL
levels and recurrent ischemic lesions in 6-month post-stroke
brain MRI scans. Recurrent lesions increased the serum NfL
levels during the follow-up period. It should be noted that
there was also a relationship between the 6-month post-stroke
serumNfL levels andMRI findings of secondary neurodegen-
eration. Moreover, the results showed a relationship between
increased serum NfL levels and the shift of MD toward higher
levels in the main white matter tracts on the same side of the
body as the infarct [148].
Huntington’s Disease
In one study, they evaluated the levels of mutant huntington
(mHTT) and NfL proteins in CSF and blood, as well as the
clinical findings and MRI scans in HD mutation carriers, both
before and after symptoms emerged [149]. Annual MRI scans
were performed in the HD mutation carriers using standard-
ized 3-T T1 volumetric MRI. The demographic, clinical, and
biochemical profiles of the patients were the same as those
that did not receive MRI scans. Moreover, the patients
underwent CSF mHTT, CSF-NfL, and plasma NfL measure-
ment. There was a relationship between the CSF-NfL levels
and pre-specified MRI volume measurements of the whole
brain, white matter, gray matter, and caudate regions, which
all were computed as tissue lesion volume (TIV) and age-
related percentages. The age and the number of CAG repeats
were correlated with MRI findings in the gray matter and
caudate. The serum NfL levels showed a relationship with
whole brain, gray matter, and caudate volumes. At any given
time point, the serum NfL levels showed a relationship with
clinical and MRI measures. According to the results from the
simultaneous assessment of CSF-mHTT, CSF-NfL, and se-
rum NfL in the HD-CSF cohort, a significant relationship
was found between the serum NfL levels and clinical severity,
while only NfL levels were related to MRI brain volume
[149].
Traumatic Brain Injury
One of leading causes of death in patients with TBI is diffuse
axonal injury (DAI). No easy and reliable approaches are
available for early diagnosis and prognosis of long-term out-
come in DAI patients [150]. Analysis was performed to assess
the relationships between the serumNfL levels andMRI in the
acute stage, as well as to follow clinical outcome andMR-DTI
parameters over 12 months. The results showed a 30-fold
increase in the mean NfL levels in the patients when compar-
ing with the controls, as well as a significant difference in the
serum NfL levels between the patients and the controls. There
was also a relationship between serum NFL and MR-DTI
indices. Moreover, higher NfL levels were found in patients
with higher trace and lower FA, suggesting the importance of
the serumNfL levels as a blood biomarker for DAI intensity in
the TBI patients [150].
Conclusions
The models for CNS and PNS diseases propose that complex
pathophysiological events occur though a sequence of multi-
ple mechanisms (i.e., neurodegeneration and axonal damage).
Following injury to the axons of the PNS or CNS, Nfs are
detectable in CSF and also in the circulation. Therefore, in-
creased levels of Nfs could be a new biomarker for diagnosis
of neurodegenerative disorders. Among different Nfs, evi-
dence suggests that there are significant correlations between
the concentrations of NfL in serum, plasma, and CSF with the
progression of CNS-related disorders. One of the crucial as-
pects of using NfL as a diagnostic biomarker is to develop
new generation assays for detecting this protein in CSF, se-
rum, and plasma. Nowadays, there are different assays for the
detection of NfL. It has been shown that the use of immuno-
blots as a first-generation assay and ELISA as a second-
generation assay for detection of Nfs is associated with limited
sensitivity. Recently, several studies showed that
electrochemiluminescence as a third-generation assay and
the single-molecule array as a fourth-generation assay are able
to the reliably measure Nfs in a wide range of biological sam-
ples. Along with biochemical biomarkers, MRI is an approved
technique for diagnosis of CNS-related disorders. There is a
relationship between the average yearly serum NfL concen-
trations and early MRI findings, and worsening fatigue rates.
The correlation of short-term and long-term outcomes with
early NfL concentrations suggests a predictive model, which
can identify patients at risk for more severe disease and who
require more aggressive therapy. Further studies will unveil
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the impacts of different therapies on the NfL concentrations.
More investigation is needed to confirm these results and to
search for additional predictors of short-term and long-term
disease progression correlated with MRI findings using ma-
chine learning and multivariate models. Furthermore, there is
a positive association between NfL and T1 and T2 relaxation
times in white matter and cortical gray matter of normal ap-
pearance, which reinforces the utility of serum NfL to help
diagnose diffuse white matter pathologies, although these as-
sociations require to be validated in larger studies. Taken to-
gether, the correlation between MRI metrics and NfL concen-
trations could be used as a powerful predictor for detection
and monitoring of CNS-related disorders.
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